Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-065640
Filing Date
2025-05-07
Accepted
2025-05-07 16:07:08
Documents
53
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q atyr-20250331.htm   iXBRL 10-Q 1895059
2 EX-31.1 atyr-ex31_1.htm EX-31.1 12312
3 EX-31.2 atyr-ex31_2.htm EX-31.2 12368
4 EX-32.1 atyr-ex32_1.htm EX-32.1 8458
5 EX-32.2 atyr-ex32_2.htm EX-32.2 8090
  Complete submission text file 0000950170-25-065640.txt   7831727

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atyr-20250331.xsd EX-101.SCH 1156203
55 EXTRACTED XBRL INSTANCE DOCUMENT atyr-20250331_htm.xml XML 1316940
Mailing Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121
Business Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121 8587318389
aTYR PHARMA INC (Filer) CIK: 0001339970 (see all company filings)

EIN.: 203435077 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37378 | Film No.: 25921338
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)